- Home
- TENX vs PMN Comparison
TENX vs PMN Comparison
Compare TENX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- PMN
- Stock Information
- Founded
- TENX 1967
- PMN 2004
- Country
- TENX United States
- PMN Canada
- Employees
- TENX N/A
- PMN N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- TENX Health Care
- PMN Health Care
- Exchange
- TENX Nasdaq
- PMN Nasdaq
- Market Cap
- TENX 21.6M
- PMN 18.8M
- IPO Year
- TENX N/A
- PMN N/A
- Fundamental
- Price
- TENX $5.68
- PMN $0.51
- Analyst Decision
- TENX Strong Buy
- PMN Strong Buy
- Analyst Count
- TENX 3
- PMN 2
- Target Price
- TENX $16.00
- PMN $4.50
- AVG Volume (30 Days)
- TENX 12.6K
- PMN 55.0K
- Earning Date
- TENX 05-14-2025
- PMN 05-12-2025
- Dividend Yield
- TENX N/A
- PMN N/A
- EPS Growth
- TENX N/A
- PMN N/A
- EPS
- TENX N/A
- PMN N/A
- Revenue
- TENX N/A
- PMN N/A
- Revenue This Year
- TENX N/A
- PMN N/A
- Revenue Next Year
- TENX N/A
- PMN N/A
- P/E Ratio
- TENX N/A
- PMN N/A
- Revenue Growth
- TENX N/A
- PMN N/A
- 52 Week Low
- TENX $2.77
- PMN $0.51
- 52 Week High
- TENX $7.89
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- TENX 49.30
- PMN 37.42
- Support Level
- TENX $5.49
- PMN $0.48
- Resistance Level
- TENX $5.87
- PMN $0.59
- Average True Range (ATR)
- TENX 0.27
- PMN 0.07
- MACD
- TENX 0.03
- PMN -0.01
- Stochastic Oscillator
- TENX 52.04
- PMN 14.00
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.